Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2008 2
2009 4
2010 2
2011 7
2012 7
2013 13
2014 14
2015 16
2016 8
2017 14
2018 18
2019 14
2020 19
2021 20
2022 31
2023 16
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant treatment with S-1 in patients after R0-resection of adenocarcinoma of the stomach and esophagogastric junction - A multicenter phase I/II feasibility study (GMBH-STO-0114).
Heinrich K, Heinemann V, Stintzing S, Müller L, Ettrich TJ, Buechner-Steudel P, Geißler M, Trojan J, Moosmann N, Folprecht G, Schmidt J, Kanzler S, Kullmann F, Moulin JC, Werner J, Angele MK, Probst V, Held S, Schulz C, Boukovala M. Heinrich K, et al. Among authors: stintzing s. Oncol Res Treat. 2024 Apr 2. doi: 10.1159/000538143. Online ahead of print. Oncol Res Treat. 2024. PMID: 38565089
Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Other Gastrointestinal Tumors-The CONKO 020 Investigation.
Meyer-Knees JW, Falkenthal J, Geisel D, Neumann CCM, Hilfenhaus G, Stephan LU, Schöning W, Malinka T, Pratschke J, Stintzing S, Pelzer U. Meyer-Knees JW, et al. Among authors: stintzing s. Cancers (Basel). 2024 Mar 18;16(6):1194. doi: 10.3390/cancers16061194. Cancers (Basel). 2024. PMID: 38539528 Free PMC article.
Enhancement of colorectal cancer therapy through interruption of the HSF1-HSP90 axis by p53 activation or cell cycle inhibition.
Isermann T, Schneider KL, Wegwitz F, De Oliveira T, Conradi LC, Volk V, Feuerhake F, Papke B, Stintzing S, Mundt B, Kühnel F, Moll UM, Schulz-Heddergott R. Isermann T, et al. Among authors: stintzing s. bioRxiv [Preprint]. 2024 Feb 26:2024.02.22.581507. doi: 10.1101/2024.02.22.581507. bioRxiv. 2024. PMID: 38464125 Free PMC article. Preprint.
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
Yoshino T, Hooda N, Younan D, Muro K, Shitara K, Heinemann V, O'neil BH, Herrero FR, Peeters M, Soeda J, Suh M, Reichert H, Mezzi K, Fryzek J, Chia V, Rehn M, Stintzing S. Yoshino T, et al. Among authors: stintzing s. Eur J Cancer. 2024 May;202:113975. doi: 10.1016/j.ejca.2024.113975. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38442645 Review.
VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.
Kreutzinger V, Pankow A, Boyadzhieva Z, Schneider U, Ziegeler K, Stephan LU, Kübke JC, Schröder S, Oberender C, le Coutre P, Stintzing S, Jelas I. Kreutzinger V, et al. Among authors: stintzing s. J Clin Med. 2024 Feb 12;13(4):1049. doi: 10.3390/jcm13041049. J Clin Med. 2024. PMID: 38398362 Free PMC article.
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A, Kind AJ, Sers C, Mamlouk S, Müller L, Karthaus M, Fruehauf S, Graeven U, Fischer von Weikersthal L, Sommerhäuser G, Kasper S, Hoppe B, Kurreck A, Held S, Heinemann V, Horst D, Jarosch A, Stintzing S, Trarbach T, Modest DP. Stahler A, et al. Among authors: stintzing s. Clin Cancer Res. 2024 Apr 1;30(7):1256-1263. doi: 10.1158/1078-0432.CCR-23-3023. Clin Cancer Res. 2024. PMID: 38289994 Clinical Trial.
A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.
Tabernero J, Yoshino T, Stintzing S, de Gramont A, Gibbs P, Jonker DJ, Nygren P, Papadimitriou C, Prager GW, Tell R, Lenz HJ. Tabernero J, et al. Among authors: stintzing s. Cancer Res Commun. 2024 Jan 4;4(1):28-37. doi: 10.1158/2767-9764.CRC-23-0361. Cancer Res Commun. 2024. PMID: 38059497 Free PMC article. Clinical Trial.
Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
Sommerhäuser G, Karthaus M, Kurreck A, Ballhausen A, Meyer-Knees JW, Fruehauf S, Graeven U, Mueller L, Koenig AO, Weikersthal LFV, Goekkurt E, Haas S, Stahler A, Heinemann V, Held S, Alig AHS, Kasper-Virchow S, Stintzing S, Trarbach T, Modest DP. Sommerhäuser G, et al. Among authors: stintzing s. Int J Cancer. 2024 Mar 1;154(5):863-872. doi: 10.1002/ijc.34760. Epub 2023 Oct 15. Int J Cancer. 2024. PMID: 37840339
192 results